Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy

Purpose Due to tumor heterogeneity, immunohistochemistry (IHC) showed poor accuracy in detecting the expression of programmed cell death ligand-1 (PD-L1) in patients. Positron emission tomography (PET) imaging is considered as a non-invasive technique to detect PD-L1 expression at the molecular level visually, real-timely and quantitatively. This study aimed to develop novel peptide-based radiotracers [Ga-68]/[F-18]AlF-NOTA-IMB for accurately detecting the PD-L1 expression and guiding the cancer immunotherapy.Methods NOTA-IMB was prepared by connecting 2,2 '-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)- 2-oxoethyl)-1,4,7-triazonane-1,4-diyl) diacetic acid (NOTA-NHS) with PD-L1-targeted peptide IMB, and further radiolabeled with Ga-68 or F-18-AlF. In vitro binding assay was conducted to confirm the ability of [Ga-68]/[F-18]AlF-NOTA-IMB to detect the expression of PD-L1. In vivo PET imaging of [Ga-68]NOTA-IMB and [F-18]AlF-NOTA-IMB in different tumor-bearing mice was performed, and dynamic changes of PD-L1 expression level induced by immunotherapy were monitored. Radioautography, western blotting, immunofluorescence staining and biodistribution analysis were carried out to further evaluate the specificity of radiotracers and efficacy of PD-L1 antibody immunotherapy.Results [Ga-68]NOTA-IMB and [F-18]AlF-NOTA-IMB were both successfully prepared with high radiochemical yield (> 95% and > 60%, n = 5) and radiochemical purity (> 95% and > 98%, n = 5). Both tracers showed high affinity to human and murine PD-L1 with the dissociation constant (K-d) of 1.00 +/- 0.16/1.09 +/- 0.21 nM (A375-hPD-L1, n = 3) and 1.56 +/- 0.58/1.21 +/- 0.39 nM (MC38, n = 3), respectively. In vitro cell uptake assay revealed that both tracers can specifically bind to PD-L1 positive cancer cells A375-hPD-L1 and MC38 (5.45 +/- 0.33/3.65 +/- 0.15%AD and 5.87 +/- 0.27/2.78 +/- 0.08%AD at 120 min, n = 3). In vivo PET imaging and biodistribution analysis showed that the tracer [Ga-68]NOTA-IMB and [F-18]AlF-NOTA-IMB had high accumulation in A375-hPD-L1 and MC38 tumors, but low uptake in A375 tumor. Treatment of Atezolizumab induced dynamic changes of PD-L1 expression in MC38 tumor-bearing mice, and the tumor uptake of [Ga-68]NOTA-IMB decreased from 3.30 +/- 0.29%ID/mL to 1.58 +/- 0.29%ID/mL (n = 3, P = 0.026) after five treatments. Similarly, the tumor uptake of [F-18]AlF-NOTA-IMB decreased from 3.27 +/- 0.63%ID/mL to 0.89 +/- 0.18%ID/mL (n = 3, P = 0.0004) after five treatments. However, no significant difference was observed in the tumor uptake before and after PBS treatment. Biodistribution, radioautography, western blotting and immunofluorescence staining analysis further demonstrated that the expression level of PD-L1 in tumor-bearing mice treated with Atezolizumab significantly reduced about 3 times and correlated well with the PET imaging results.Conclusion [Ga-68]NOTA-IMB and [F-18]AlF-NOTA-IMB were successfully prepared for PET imaging the PD-L1 expression noninvasively and quantitatively. Dynamic changes of PD-L1 expression caused by immunotherapy can be sensitively detected by both tracers. Hence, the peptide-based radiotracers [Ga-68]NOTA-IMB and [F-18]AlF-NOTA-IMB can be applied for accurately detecting the PD-L1 expression in different tumors and monitoring the efficacy of immunotherapy.